Early real-world outcomes of AcrySof IQ PanOptix trifocal IOL show high patient satisfaction

ByRobert Linnehan

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Patients who received the first FDA-approved trifocal IOL reported high satisfaction with the lens, but some can experience some contrast or quality diminution even with final 20/20 vision, according to a speaker at the virtual American Society of Cataract and Refractive Surgery meeting.

“Some halos are present in 50% of patients, but most of these patients would still choose this lens again,” Sheri L. Rowen, MD, ABO, said.

Rowen and her colleague, Duna Raoof, MD, implanted the AcrySof IQ PanOptix trifocal IOL (Alcon) in patients first starting in September 2019 and evaluated distance, intermediate and near visual acuities at 1-week and 1- to 3-month postoperative visits. Patients were given a survey to determine glare, halos, need for glasses and happiness levels and if they would choose to receive the same lens again.

In 89 patients at 1 week, 79% of patients experienced 20/30 or better monocular uncorrected distance visual acuity, and 94% experienced monocular corrected distance visual acuity of 20/25 or bette

At 1 to 3 months, postoperative monocular uncorrected distance visual acuity was 20/40 or better in 93% of 55 patients. For monocular corrected distance visual acuity, 85% of patients were 20/25 or better. Monocular uncorrected intermediate visual acuity was 20/20 or better in 72% of 48 patients, Rowen said.

In a survey of 57 patients, 68.2% reported no or mild halos compared with 30.8% who reported moderate to severe halos. Additionally, 92% of patients reported a quality of vision of 8 or greater on a 1 to 10 scale. Finally, 95% of patients reported they would have the same IOL implanted again, she said.

“We want to look out for contrast. This seems to be the No. 1 factor that creates a low happiness score. Halos will appear in 50% of patients, so I tell everyone they will have them, and they’re pleasantly surprised when they’re mild or nonexistent, and they have not been debilitating for the most part. None were severe,” Rowen said. – by Robert Linnehan

Reference:

Rowen SL. Early real-world outcomes of the first U.S. approved trifocal IOL. Presented at: American Society of Cataract and Refractive Surgery meeting; May 16-17, 2020 (virtual meeting).

Disclosure: Rowen reports she has relevant financial disclosures with Alcon, Allergan, Bausch + Lomb, Johnson & Johnson, Orasis and Novartis.